$62 M

ACER Mkt cap, 12-Aug-2020
Acer Therapeutics Net income (Q1, 2020)-4.9 M
Acer Therapeutics EBIT (Q1, 2020)-5 M
Acer Therapeutics Cash, 31-Mar-20207 M
Acer Therapeutics EV55.5 M

Acer Therapeutics Income Statement

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

1.3m1.3m2.6m2.9m

Revenue growth, %

0%101%

R&D expense

3.3m6.3m9.2m12.1m10.0m6.5m8.7m12.5m13.9m

General and administrative expense

2.4m2.5m3.7m3.8m4.3m3.1m5.2m9.3m16.0m

Operating expense total

5.7m8.8m12.9m16.0m14.3m9.6m13.9m21.7m29.9m

Depreciation and amortization

238.1k

EBIT

(6.0m)(9.1m)(11.9m)(15.1m)(12.1m)(8.0m)(13.9m)(21.7m)(29.9m)

EBIT margin, %

(941%)(1185%)(473%)(275%)

Interest expense

3.1k350.3k874.0245.1k987.0

Interest income

932.0280.015.0k15.5k5.9k14.8k412.6k471.3k

Income tax expense

Net Income

(6.0m)(8.9m)(16.7m)(15.1m)(12.0m)(8.0m)(14.2m)(21.3m)(29.4m)

Acer Therapeutics Balance Sheet

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

7.1m592.0k23.6m9.9m12.6m3.4m15.6m41.7m12.1m

Prepaid Expenses

124.8k132.2k1.1m758.9k995.1k881.9k1.1m807.4k

Inventories

Current Assets

7.2m1.7m24.8m10.7m13.6m3.8m16.5m42.7m12.9m

PP&E

1.0m1.3m1.3m1.1m837.9k63.0k130.9k194.0k

Goodwill

7.6m7.6m7.6m

Total Assets

8.3m4.1m26.2m11.8m14.4m3.9m24.4m50.7m21.5m

Accounts Payable

476.3k412.1k696.2k702.5k739.9k378.0k95.9k1.0m561.1k

Short-term debt

148.3k263.4k

Current Liabilities

1.1m886.0k3.3m3.1m4.8m1.2m2.8m

Long-term debt

318.7k326.3k

Total Debt

318.7k589.7k

Total Liabilities

1.1m1.3m5.7m4.4m4.8m1.2m2.0m5.6m3.1m

Common Stock

230.5k62.5k275.5k282.3k69.8k75.0k1.0k1.0k

Preferred Stock

Additional Paid-in Capital

107.6m112.4m146.6m148.5m162.9m164.0m47.8m91.9m94.6m

Retained Earnings

(141.3m)(153.3m)(161.3m)(25.6m)(46.8m)(76.3m)

Total Equity

7.2m2.9m20.6m7.4m9.6m2.7m22.3m45.1m18.4m

Financial Leverage

1.1 x1.4 x1.3 x1.6 x1.5 x1.4 x1.1 x1.1 x1.2 x

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

9.9m8.6m4.7m1.6m2.2m7.8m5.0m20.2m19.7m16.2m13.6m9.6m18.3m15.6m10.0m7.8m5.8m2.8m1.8m8.4m12.4m8.3m46.2m31.8m23.5m16.1m7.0m

Prepaid Expenses

119.6k105.6k1.0m953.4k1.2m365.1k307.0k1.3m1.6m1.5m727.8k683.5k403.6k329.3k932.4k339.8k224.8k237.3k156.0k836.8k826.4k571.2k1.1m778.7k792.2k972.1k624.5k

Current Assets

10.0m8.7m5.7m2.5m3.4m9.0m6.7m21.5m21.2m17.7m14.4m10.3m18.7m16.2m10.9m8.2m6.0m3.1m2.0m9.2m13.2m8.9m47.3m32.6m24.3m17.1m7.6m

PP&E

930.1k953.2k1.4m1.4m1.3m1.2m1.2m1.2m1.3m1.2m1.2m1.0m918.9k886.9k765.8k700.8k648.8k5.1k66.5k67.1k131.3k210.3k186.0k158.8k176.3k

Goodwill

7.6m7.6m7.6m7.6m7.6m7.6m7.6m7.6m

Total Assets

10.9m9.7m7.1m3.9m6.0m11.0m8.7m22.8m22.7m19.1m15.6m11.3m19.6m17.1m11.7m9.4m7.2m3.1m2.0m17.0m21.0m16.8m55.3m41.0m32.8m25.5m16.1m

Accounts Payable

495.8k429.6k1.7m556.1k534.4k830.7k1.2m914.3k715.3k835.6k372.0k1.2m1.1m1.0m562.2k577.8k1.0m298.1k6.9k539.4k325.5k861.1k595.4k61.2k1.5m29.6k344.8k

Short-term debt

93.2k37.5k91.9k26.5k264.5k

Current Liabilities

754.8k730.5k2.0m908.5k3.4m3.2m3.8m3.4m3.3m3.7m3.5m5.3m5.0m5.0m4.0m3.5m2.8m818.3k368.5k3.0m4.9m2.4m1.8m

Long-term debt

301.4k418.7k245.2k311.5k264.3k271.0k

Total Debt

301.4k418.7k93.2k37.5k91.9k26.5k245.2k311.5k264.3k535.5k

Total Liabilities

2.0m908.5k3.7m6.9m7.3m6.1m5.3m5.5m5.0m7.5m6.4m5.7m4.0m3.5m2.8m818.3k368.5k2.3m2.5m2.7m2.2m3.2m5.2m2.7m2.1m

Common Stock

230.5k230.5k230.5k230.5k230.5k79.9k79.9k227.3k276.6k276.6k281.8k282.6k533.9k68.6k69.8k70.5k71.4k76.6k76.6k645.075.0k750.01.0k1.0k1.0k1.0k1.0k

Preferred Stock

Additional Paid-in Capital

107.4m107.5m107.9m108.0m109.7m117.7m118.0m139.0m147.0m147.4m148.3m148.2m160.9m162.3m163.0m163.4m163.9m164.4m164.5m36.1m48.0m48.4m91.4m92.6m93.4m94.0m95.3m

Retained Earnings

(148.2m)(151.0m)(155.5m)(157.6m)(159.6m)(162.2m)(162.9m)(21.3m)(29.5m)(34.4m)(38.3m)(54.8m)(65.8m)(71.1m)(81.2m)

Total Equity

10.2m9.0m5.0m3.0m2.3m4.0m1.3m16.7m17.4m13.6m10.6m3.8m13.2m11.4m7.6m5.9m4.3m2.2m1.6m14.8m18.6m14.1m53.1m37.8m27.6m22.9m14.1m

Financial Leverage

1.1 x1.1 x1.4 x1.3 x2.6 x2.7 x6.5 x1.4 x1.3 x1.4 x1.5 x3 x1.5 x1.5 x1.5 x1.6 x1.7 x1.4 x1.2 x1.2 x1.1 x1.2 x1 x1.1 x1.2 x1.1 x1.1 x

Acer Therapeutics Cash Flow

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(6.0m)(8.9m)(16.7m)(15.1m)(12.0m)(8.0m)(14.2m)(21.3m)(29.4m)

Depreciation and Amortization

210.3k303.7k335.6k387.8k351.4k238.1k4.0k27.7k58.3k

Accounts Receivable

26.2k

Accounts Payable

(13.0k)(71.4k)147.9k6.3k37.4k(361.9k)(287.5k)938.0k(472.7k)

Cash From Operating Activities

(5.0m)(8.9m)(6.1m)(14.2m)(10.5m)(9.2m)(14.1m)(16.6m)(29.5m)

Purchases of PP&E

(296.9k)(550.4k)(259.2k)(190.9k)(92.3k)(1.2k)(62.8k)(95.6k)(179.0k)

Cash From Investing Activities

(296.9k)(1.6m)740.8k(190.9k)(92.3k)(1.2k)967.3k(95.6k)(179.0k)

Short-term Borrowings

(450.0k)

Long-term Borrowings

(35.6k)

Cash From Financing Activities

8.6m4.0m28.4m648.2k13.3m65.4k26.9m42.7m92.3k

Net Change in Cash

3.3m(6.5m)23.1m(13.7m)2.7m(9.1m)13.8m26.0m(29.6m)

Interest Paid

3.1k1.9k19.6k2.0k2.3k3.3k

Income Taxes Paid

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

(2.8m)(4.1m)(2.4m)(4.5m)(6.9m)(4.2m)(7.2m)(12.9m)(3.7m)(7.8m)(11.7m)(3.4m)(6.8m)(9.6m)(2.2m)(4.3m)(6.3m)(926.3k)(1.6m)(10.0m)(4.0m)(8.8m)(12.8m)(8.0m)(19.0m)(24.3m)(4.9m)

Depreciation and Amortization

100.4k157.3k67.4k143.9k225.4k78.3k167.2k258.1k95.6k194.2k291.6k97.0k191.0k280.0k72.6k138.2k190.3k2.7k6.2k11.0k16.6k9.5k27.1k40.6k17.7k

Accounts Payable

100.5k59.8k1.0m52.3k(130.3k)418.6k635.4k216.9k(12.6k)132.6k(324.2k)(61.0k)446.2k315.7k(186.0k)(162.0k)278.6k(79.9k)(371.1k)156.0k229.7k765.2k499.6k(972.7k)505.0k(1.0m)(216.3k)

Cash From Operating Activities

(2.3m)(3.5m)(2.2m)(5.1m)(7.3m)3.0m428.7k(2.5m)(3.9m)(7.3m)(10.5m)(222.2k)(3.7m)(6.8m)(2.5m)(4.6m)(6.9m)(1.0m)(2.0m)(9.9m)(3.2m)(7.2m)(12.0m)(9.8m)(18.1m)(25.5m)(5.1m)

Purchases of PP&E

(172.1k)(284.0k)(245.8k)(473.1k)(512.0k)(2.6k)(22.9k)(214.2k)(75.9k)(127.2k)(149.2k)(6.4k)(11.8k)(69.9k)(485.0)(1.2k)(1.2k)(2.5k)(9.8k)(15.1k)(84.9k)(88.9k)(135.0k)(126.1k)

Cash From Investing Activities

(172.1k)(284.0k)(245.8k)(473.1k)(1.5m)497.4k477.1k785.8k(75.9k)(127.2k)(149.2k)(6.4k)(11.8k)(69.9k)(485.0)(1.2k)(1.2k)50.0k50.0k1.0m(9.8k)(15.1k)(84.9k)(88.9k)(135.0k)(126.1k)

Short-term Borrowings

(35.6k)(35.6k)(450.0k)(450.0k)(450.0k)(55.1k)(110.9k)(148.3k)(64.8k)(130.1k)

Cash From Financing Activities

8.6m8.6m3.9m3.7m3.5m21.3m648.2k(104.9k)12.1m12.6m(82.7k)(161.1k)106.9k348.9k283.6k15.4m(38.7k)(38.7k)42.6m92.3k92.3k

Net Change in Cash

6.1m4.8m(2.4m)(5.5m)(4.9m)7.2m4.4m19.6m(4.0m)(7.4m)(10.0m)(333.5k)8.4m5.7m(2.6m)(4.7m)(6.8m)(622.3k)(1.6m)6.6m(3.3m)(7.3m)30.5m(9.8m)(18.2m)(25.5m)(5.1m)

Interest Paid

2.0k2.6k487.0973.01.5k18.6k19.1k19.6k958.0747.01.0k50.01.4k2.2k2.4k1.2k1.8k

Income Taxes Paid

Acer Therapeutics Ratios

USDQ2, 2011

Financial Leverage

1.1 x